SCHEMBL25047

SCHEMBL25047

Cc1cc(C)c(S(=O)(=O)ONC(=O)OC(C)(C)C)c(C)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
LCK P06239 6/20 0.41
CA1 P00915 3/20 0.41
CA2 P00918 3/20 0.41
MMP1 P03956 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
F2 P00734 3/20 0.41
PRSS1 P07477 3/20 0.41
PRSS2 P07478 3/20 0.41
PRSS3 P35030 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24713046 0.83 CA1 (0.34) NFKB1NFKB2RELALCKCA1
SCHEMBL17004464 0.81 MAPT (0.44) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL26007894 0.81 EPHX2 (0.36) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL6121500 0.80 CA1 (0.48) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL29144118 0.80 SMN1; SMN2 (0.46) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL14736112 0.79 MAPT (0.54) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL31636878 0.78 NFKB1 (0.40) NFKB1NFKB2RELAMAPTLMNA
SCHEMBL4289710 0.78 CA1 (0.51) NFKB1NFKB2RELAMAPTLCK
SCHEMBL23172334 0.78 L3MBTL1 (0.47) MAPTMEN1LMNAKMT2ASMN1; SMN2
SCHEMBL6851706 0.77 NFKB1 (0.39) NFKB1NFKB2RELAMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 346 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4746964-A1 NEW PYRAZOLOPYRIDINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2026-05-27 EP disclosed
WO-2026046976-A1 PYRAZOLOPYRIDINE PHOSPHATE ESTERS FOR MODULATING SALT-INDUCIBLE KINASE (SIK) F. HOFFMANN-LA ROCHE AG (CH) 2026-03-05 WO disclosed
EP-4688778-A1 1H-PYRROLO[2,3-B]PYRIDIN-4-YL]-2-OXOPYRROLIDINE-3-CARBONITRILE DERIVATIVES AS TYROSINE KINASE 2 (TYK2) INHIBITORS FOR THE TREATMENT OF INFLAMMATORY DISEASES Biogen MA Inc. (US) 2026-02-11 EP disclosed
US-12522603-B2 Inhibitors of gas for treating autoinflammatory diseases and cancer metastasis THE ROCKEFELLER UNIVERSITY (US) 2026-01-13 US disclosed
EP-4638448-A1 CONJUGATES COMPRISING ANTIFUNGALS AND CASEIN KINASE (CK1) INHIBITORS AND METHODS OF USE THEREOF Bright Angel Therapeutics Inc. (CA) 2025-10-29 EP disclosed
US-20250325677-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-23 US disclosed
US-20250320205-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed
US-20250320206-A1 STAT6 DEGRADERS GILEAD SCIENCES INC (US) 2025-10-16 US disclosed
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2025-10-14 US disclosed
EP-4612152-A1 PREPARATION OF TRIAZOLOPYRIDINE DERIVATIVES AS NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS Merck Sharp & Dohme LLC (US) 2025-09-10 EP disclosed
WO-2002016359-A1 FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2002-02-28 WO disclosed
EP-1157025-A1 PYRAZOLOPYRIDINES GLAXO GROUP LIMITED (GB) 2001-11-28 EP disclosed
EP-1127058-A1 PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS GLAXO GROUP LIMITED (GB) 2001-08-29 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed
WO-2000052008-A1 PYRAZOLOPYRIDINES GLAXO GROUP LIMITED (GB) 2000-09-08 WO disclosed
WO-2000026216-A1 PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX-2 INHIBITORS GLAXO GROUP LIMITED (GB) 2000-05-11 WO disclosed
US-5661108-A CONTROLLING PLANT GROWTH FMC CORPORATION (US) 1997-08-26 US disclosed
US-5521147-A HERBICIDES FMC CORPORATION (US) 1996-05-28 US disclosed
US-5296505-A Reacting dithianepropenol with ethynyl-beta-ionol in presence of organomagnesium compound, hydrogenating triple bond, reducing diol with low-valency titanium L'OREAL (FR) 1994-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12441724-B2 Inhibitors of plasma kallikrein and uses thereof KLKB1, KLK1, KLK5 NFKB1 3010/4885NFKB2 3934/4885RELA 4657/4885
US-20250325677-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 NFKB1 369/4885NFKB2 168/4885RELA 31/4885
US-20250320205-A1 STAT6 DEGRADERS STAT6, STAT1, STAT5B NFKB1 318/4885NFKB2 138/4885RELA 29/4885
US-20250320206-A1 STAT6 DEGRADERS STAT6, STAT5B, STAT1 NFKB1 369/4885NFKB2 168/4885RELA 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.